|Page (1) of 1 - 10/11/12||email article||print page|
Intercept Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept.
|Intercept Pharmaceuticals Announces IPO Pricing|
Source:GrabNetworks (c). All Rights Reserved